{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T17:59:06Z","timestamp":1771351146122,"version":"3.50.1"},"reference-count":41,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2024,3,10]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>Glucocorticoids are commonly used for neurological disorders, but they can have significant adverse effects, including adrenal insufficiency, hyperglycaemia, osteoporosis and increased infection risk. Long-term use of corticosteroids requires the prescriber to plan risk mitigation, including monitoring and often coprescribing. This article highlights the potential risks of corticosteroid prescribing and draws together up-to-date guidance with multispecialty input to clarify ways of reducing those risks. We discuss home blood glucose monitoring and consider a steroid safety checklist to promote safer steroid prescribing.<\/jats:p>","DOI":"10.1136\/pn-2023-003855","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T13:25:21Z","timestamp":1711718721000},"page":"289-295","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Glucocorticoid prescribing in neurology"],"prefix":"10.1136","volume":"24","author":[{"given":"Andrew P","family":"Jones","sequence":"first","affiliation":[{"name":"Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Debono","sequence":"additional","affiliation":[{"name":"Endocrinology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Walsh","sequence":"additional","affiliation":[{"name":"Metabolic Bone Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Smith","sequence":"additional","affiliation":[{"name":"Diabetes Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leanne","family":"Hunt","sequence":"additional","affiliation":[{"name":"Diabetes Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona M","family":"McKevitt","sequence":"additional","affiliation":[{"name":"Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"key":"2025090411021852000_24.4.289.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196802222780801"},{"key":"2025090411021852000_24.4.289.2","unstructured":"National Institute for Health and Care Excellence . Clinical knowledge summary: corticosteroids- oral 2020 [last revised in Jan 2024]. 2024 Available: https:\/\/cks.nice.org.uk\/topics\/corticosteroids-oral"},{"key":"2025090411021852000_24.4.289.3","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","article-title":"British society for rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025090411021852000_24.4.289.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106118"},{"key":"2025090411021852000_24.4.289.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61684-0"},{"key":"2025090411021852000_24.4.289.6","unstructured":"NHS England . Steroid emergency card to support early recognition and treatment of adrenal crisis in adults; 2020."},{"key":"2025090411021852000_24.4.289.7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.7861\/clinmed.2019-0324","article-title":"Guidance for the prevention and emergency management of adult patients with adrenal insufficiency","volume":"20","author":"Simpson","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"2025090411021852000_24.4.289.8","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/bmj.n1380","article-title":"Glucocorticoid induced adrenal insufficiency","volume":"374","author":"Prete","year":"2021","journal-title":"BMJ"},{"key":"2025090411021852000_24.4.289.9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1218"},{"key":"2025090411021852000_24.4.289.10","doi-asserted-by":"crossref","unstructured":"Menzies-Gow A , Corren J , Bel EH , et al . Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: ponente trial. ERJ Open Res 2019;5. doi:10.1183\/23120541.00009-2019","DOI":"10.1183\/23120541.00009-2019"},{"key":"2025090411021852000_24.4.289.11","doi-asserted-by":"crossref","unstructured":"Debono M , Elder CJ , Lewis J , et al . Home waking salivary cortisone to screen for adrenal insufficiency. NEJM Evid 2023;2. doi:10.1056\/EVIDoa2200182","DOI":"10.1056\/EVIDoa2200182"},{"key":"2025090411021852000_24.4.289.12","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v6.i8.1073"},{"key":"2025090411021852000_24.4.289.13","doi-asserted-by":"publisher","DOI":"10.1159\/000365892"},{"key":"2025090411021852000_24.4.289.14","unstructured":"Joint British Diabetes Societies for Inpatient Care . Management of hyperglycaemia and steroid (glucocorticoid) therapy; 2023."},{"key":"2025090411021852000_24.4.289.15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2729"},{"key":"2025090411021852000_24.4.289.16","unstructured":"National Institute for Health and Care Excellence . Type 1 diabetes in adults: diagnosis and management. 2015. Available: https:\/\/www.nice.org.uk\/guidance\/ng17\/chapter\/recommendations#blood-glucose-management2023"},{"key":"2025090411021852000_24.4.289.17","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1588-2"},{"key":"2025090411021852000_24.4.289.18","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00198-015-3455-9","article-title":"Fracture risk in oral glucocorticoid users: a bayesian meta-regression leveraging control arms of osteoporosis clinical trials","volume":"27","author":"Amiche","year":"2016","journal-title":"Osteoporos Int"},{"key":"2025090411021852000_24.4.289.19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s40263-014-0173-3","article-title":"Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions","volume":"28","author":"Gupta","year":"2014","journal-title":"CNS Drugs"},{"key":"2025090411021852000_24.4.289.20","doi-asserted-by":"crossref","first-page":"612366","DOI":"10.3389\/fpsyg.2020.612366","article-title":"Effects of neurological disorders on bone health","volume":"11","author":"Kelly","year":"2020","journal-title":"Front Psychol"},{"key":"2025090411021852000_24.4.289.21","doi-asserted-by":"crossref","unstructured":"Kim SW , Kim EH , Lee J , et al . Risk of osteoporosis in patients with chronic inflammatory neuropathy- a population-based cohort study. Sci Rep 2019;9. doi:10.1038\/s41598-019-45591-4","DOI":"10.1038\/s41598-019-45591-4"},{"key":"2025090411021852000_24.4.289.22","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1212\/WNL.0000000000000804","article-title":"Increased risk of osteoporosis in patients with myasthenia gravis: a population-based cohort study","volume":"83","author":"Yeh","year":"2014","journal-title":"Neurology"},{"key":"2025090411021852000_24.4.289.23","doi-asserted-by":"crossref","DOI":"10.1007\/s11657-022-01061-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"17","author":"Gregson","year":"2022","journal-title":"Arch Osteoporos"},{"key":"2025090411021852000_24.4.289.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.01.373"},{"key":"2025090411021852000_24.4.289.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1524-7"},{"key":"2025090411021852000_24.4.289.26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/BOT.0000000000000539","article-title":"A review of atypical femoral fractures from a tertiary care teaching hospital: an alarming trend","volume":"30","author":"Black","year":"2016","journal-title":"J Orthop Trauma"},{"key":"2025090411021852000_24.4.289.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223335"},{"key":"2025090411021852000_24.4.289.28","unstructured":"Public Health England . Chapter 28a: shingles (herpes zoster). In: Immunisation against infectious disease. 2023."},{"key":"2025090411021852000_24.4.289.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.21705"},{"key":"2025090411021852000_24.4.289.30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/23744235.2019.1682187","article-title":"High risk of activation of latent tuberculosis infection in rheumatic disease patients","volume":"52","author":"Long","year":"2020","journal-title":"Infectious Diseases"},{"key":"2025090411021852000_24.4.289.31","doi-asserted-by":"crossref","unstructured":"Koutsianas C , Thomas K , Vassilopoulos D . Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis 2020;12. doi:10.1177\/1759720X20912646","DOI":"10.1177\/1759720X20912646"},{"key":"2025090411021852000_24.4.289.32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cld.2019.04.012","article-title":"Screening and prophylaxis to prevent hepatitis B reactivation: other populations and newer agents","volume":"23","author":"Sasadeusz","year":"2019","journal-title":"Clin Liver Dis"},{"key":"2025090411021852000_24.4.289.33","unstructured":"Department of Health and Social Care . Higher-risk patients eligible for COVID-19 treatments: independent advisory group report; 2023."},{"key":"2025090411021852000_24.4.289.34","first-page":"114","article-title":"Pneumocystis carinii pneumonia among patients with neoplastic disease","volume":"7","author":"Sepkowitz","year":"1992","journal-title":"Semin Respir Infect"},{"key":"2025090411021852000_24.4.289.35","doi-asserted-by":"publisher","DOI":"10.4065\/71.1.5"},{"key":"2025090411021852000_24.4.289.36","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-002-0758-5"},{"key":"2025090411021852000_24.4.289.37","doi-asserted-by":"publisher","DOI":"10.1086\/342338"},{"key":"2025090411021852000_24.4.289.38","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0223"},{"key":"2025090411021852000_24.4.289.39","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2023-003708"},{"key":"2025090411021852000_24.4.289.40","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2013-000727"},{"key":"2025090411021852000_24.4.289.41","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"2014","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/pn-2023-003855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T18:12:05Z","timestamp":1757009525000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/pn-2023-003855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,7,16]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/pn-2023-003855"],"URL":"https:\/\/doi.org\/10.1136\/pn-2023-003855","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}